Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 351

1.

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

J Clin Psychopharmacol. 2009 Feb;29(1):26-32. doi: 10.1097/JCP.0b013e31819294cb.

PMID:
19142103
2.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
3.
4.

Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM.

J Clin Psychiatry. 2006 Sep;67(9):1323-6.

PMID:
17017817
5.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, ThiƩbaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. French.

PMID:
23246328
6.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
7.

Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.

Schneiderhan ME, Batscha CL, Rosen C.

Pharmacotherapy. 2009 Aug;29(8):975-87. doi: 10.1592/phco.29.8.975.

PMID:
19637951
8.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

9.

Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.

Barnett M, VonMuenster S, Wehring H, Popish S, McDonald K, Walker VM, Perry P.

Ann Clin Psychiatry. 2010 Feb;22(1):9-18.

PMID:
20196978
10.

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

Diabetes Care. 2009 Jun;32(6):1037-42. doi: 10.2337/dc08-1720.

11.

Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.

Weissman E, Jackson C, Schooler N, Goetz R, Essock S.

Clin Schizophr Relat Psychoses. 2012 Jan;5(4):201-7. doi: 10.3371/CSRP.5.4.4.

PMID:
22182457
12.

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

Correll CU, Frederickson AM, Kane JM, Manu P.

J Clin Psychiatry. 2006 Apr;67(4):575-83.

PMID:
16669722
13.

Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.

Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, Watson KE, Willey VJ, Stanek EJ.

Circulation. 2005 Feb 1;111(4):488-93.

14.

Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.

Sicras A, Rejas J, Navarro R, Serrat J, Blanca M.

Bipolar Disord. 2008 Jul;10(5):607-16. doi: 10.1111/j.1399-5618.2008.00599.x.

PMID:
18657245
15.

Antipsychotic medication utilization trends among Texas veterans: 1997-2002.

Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J, Mascarenas CA.

Ann Pharmacother. 2008 Sep;42(9):1229-38. doi: 10.1345/aph.1L155.

PMID:
18682544
16.

Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.

Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W.

J Clin Psychiatry. 2007 Mar;68(3):406-9.

PMID:
17388710
17.

Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.

Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, Delgado JF, Diez T, Villardaga I.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):383-8.

PMID:
17129654
18.

Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics.

Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C.

Transl Psychiatry. 2012 Jan 24;2:e71. doi: 10.1038/tp.2011.68.

19.

Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.

Sicras-Mainar A, Blanca-Tamayo M, Rejas-GutiƩrrez J, Navarro-Artieda R.

Eur Psychiatry. 2008 Mar;23(2):100-8.

PMID:
17904825
20.

Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.

Panagiotopoulos C, Ronsley R, Davidson J.

Can J Psychiatry. 2009 Nov;54(11):743-9.

PMID:
19961662
Items per page

Supplemental Content

Support Center